HIV Vaccines: where are we, where are we going, and how can we get there faster?

16 July 2010
Alan Bernstein, O.C., Ph.D. Executive Director, Global HIV Vaccine Enterprise

Estimated Number of Adults and Children Newly Infected with HIV, 2008
Western & Central Europe 30 000 [23 000 35 000] Eastern Europe & Central Asia 110 000 [100 000 130 000] East Asia 75 000 [58 000 88 000] Middle East & North Africa 35 000 [24 000 46 000] South & South-East Asia 280 000 [240 000 320 000]

North America 55 000 [36 000 61 000] Caribbean 20 000 [16 000 24 000]

Latin America 170 000 Sub-Saharan Africa [150 000 200 000] 1.9 million [1.6 2.2 million]

Oceania 3900 [2900 5100]

Total: 2.7 million (2.4 3.0 million)

Adapted from UNAIDS, December 2009

An Unsustainable Economic Situation

Prevention Approaches and Biomedical Interventions
Vaccine Education PrEP


HIV Prevention Modalities

Partner reduction



Test and treat
Adapted from A. Fauci, NIH, 2009

Drug/alcohol treatment

Effective in high-risk populations

Protection against diversity of HIV strains

GLOBALLY EFFECTIVE HIV VACCINE Durable, safe and effective Globally accessible

Adapted from M. Robb, MHRP, 2010

How an HIV Vaccine Might Work

Timeline Between Disease Identification and Vaccine Development
yellow fever jap. encephalitis tetanus diphtheria tuberculosis whooping cough polio Streptococcal meningitis Haemophilus influenza B typhoid malaria 1900 Vaccine available Partially-effective vaccine No vaccine 1920 1940 1960 1980 2000 influenza tick encephalitis chickenpox cytomegalovirus rubella measles hepatitis B mumps rotavirus hep. A hepatitis C HIV HPV

How do we Develop Vaccines?

Efficacy trials

Phase 1 and II trials

Clinical research

Product development and animal testing New vaccine strategies Fundamental research

Hope for an HIV Vaccine RV144 Modified Intention-to-Treat Analysis 
First proof of concept: a vaccine is possible  Need to understand how vaccine reduced risk of HIV acquisition  Important implications for future HIV vaccine design and testing
Source: Rerks-Ngarm et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-I Infection in Thailand. N Engl Med 2009; 361.

An Important Moment in HIV Vaccine Research

EMBARGOED UNTIL 11:15 a.m. CST Sunday, 18 July

The 2010 Plan: The Framework For A New Era of HIV Vaccine Research

‡ Developed by the Enterprise Council involving the Enterprise Science Committee and five Working Groups ‡ Input of more than 400 researchers, policy-makers, funders and advocates worldwide ‡ An agreement of partners to align their independent strategies to maximize opportunities for cooperation in HIV vaccine research

Transforming the Global HIV Vaccine Research Effort
Unified clinical trials agenda Rapid data sharing New minds and new ideas

Broaden and increase funding

Global HIV Vaccine Enterprise: Promoting Scientific Collaboration

AIDS Vaccine Asian Network


Upcoming Enterprise 2010 Plan Activities
AIDS 2010, Vienna (18 23 July) 1. Satellite Session: The Search for an HIV Vaccine: Where are we, where are we going, and how can we get there faster? 11:15 13:15, Mini Room 6 2. Press Conference: Entering the Next Phase in HIV Vaccine Research, the Future Course of the Field Monday, 19 July 12:00 13:00, Press Room 1 3. Vaccine Session: HIV Vaccines Quo Vadis? Tuesday, 20 July 14:30 16:00, Session Room 3 4. Enterprise Booth Section E, booth 476 AIDS Vaccine 2010, Atlanta (28 Sept. 1 Oct.) 1. Plenary Session: Launch of the Global HIV Vaccine Enterprise 2010 Plan Wednesday, 29 September 14:30 - 16:00

Sign up to vote on this title
UsefulNot useful